A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer

NCT02019693 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

NIH

Sponsor class

Conditions

Kidney Cancer

Interventions

DRUG: INC280

Sponsor

National Cancer Institute (NCI)